SCHEMBL3341682

SCHEMBL3341682

CC(C)Oc1nc(N)nc2ccc(-c3cccc(C#N)c3)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.53
MAP4K4 O95819 1/20 0.50
ADORA1 P30542 2/20 0.46
CYP1A2 P05177 7/20 0.45
CYP3A4 P08684 7/20 0.45
CLK4 Q9HAZ1 7/20 0.45
ALDH1A1 P00352 6/20 0.45
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
USP2 O75604 3/20 0.40
HIF1A Q16665 3/20 0.40
LMNA P02545 3/20 0.40
CYP2D6 P10635 3/20 0.40
TSHR P16473 3/20 0.40
MAPK1 P28482 3/20 0.40
HSD17B10 Q99714 3/20 0.40
CYP2C9 P11712 2/20 0.40
TP53 P04637 1/20 0.40
RECQL P46063 1/20 0.40
CYP2C19 P33261 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3340367 0.89 MAP4K4 (0.47) ADORA2AMAP4K4HRH4ATM
SCHEMBL3337685 0.84 ADORA2A (0.53) ADORA2AMAP4K4ADORA1CYP1A2CYP3A4
SCHEMBL3337252 0.82 SRC (0.51) ADORA2AMAP4K4ADORA1CYP1A2CYP3A4
SCHEMBL3334631 0.82 MAP4K4 (0.53) ADORA2AMAP4K4ADORA1MAPTATM
SCHEMBL3336558 0.81 ADORA2A (0.50) ADORA2AMAP4K4ADORA1CYP1A2CYP3A4
SCHEMBL3333937 0.80 DHFR (0.48) MAPTATM
SCHEMBL3331691 0.79 ADORA2A (0.43) ADORA2AADORA1CYP1A2CYP3A4ALDH1A1
SCHEMBL3333131 0.79 HSP90AB1 (0.47) ADORA2AMEN1KMT2AHRH4MAPT
SCHEMBL3333380 0.79 MKNK1 (0.48) MAP4K4CYP1A2CYP3A4CLK4MEN1
SCHEMBL3336166 0.78 ATM (0.39) TSHRMAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 ADORA2A 1968/4885MAP4K4 2433/4885ADORA1 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.